CA2287538A1 - Formes tronquees de proteines apparentees au facteur vegf - Google Patents

Formes tronquees de proteines apparentees au facteur vegf Download PDF

Info

Publication number
CA2287538A1
CA2287538A1 CA002287538A CA2287538A CA2287538A1 CA 2287538 A1 CA2287538 A1 CA 2287538A1 CA 002287538 A CA002287538 A CA 002287538A CA 2287538 A CA2287538 A CA 2287538A CA 2287538 A1 CA2287538 A1 CA 2287538A1
Authority
CA
Canada
Prior art keywords
vrp
truncated
subunit
sequence
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002287538A
Other languages
English (en)
Inventor
Peter Bohlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Collateral Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2287538A1 publication Critical patent/CA2287538A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention se rapporte à de nouvelles formes tronquées de protéines apparentées au facteur de croissance endothéliale vasculaire (VRP) qui servent à stimuler l'engiogenèse in vitro et in vivo. Cette invention se rapporte également à des acides nucléiques codant ces nouvelles protéines VRP tronquées et à des procédés pour produire ces protéines VRP tronquées. Des compositions pharmaceutiques contenant ces protéines VRP tronquées et des procédés de thérapie génétique utilisant les acides nucléiques qui codent ces protéines VRP tronquées peuvent servir dans le traitement des maladies cardiaques et pour la cicatrisation des plaies.
CA002287538A 1997-04-25 1998-04-20 Formes tronquees de proteines apparentees au facteur vegf Abandoned CA2287538A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84298497A 1997-04-25 1997-04-25
US08/842,984 1997-04-25
PCT/US1998/007801 WO1998049300A2 (fr) 1997-04-25 1998-04-20 Formes tronquees de proteines apparentees au facteur vegf

Publications (1)

Publication Number Publication Date
CA2287538A1 true CA2287538A1 (fr) 1998-11-05

Family

ID=25288752

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002287538A Abandoned CA2287538A1 (fr) 1997-04-25 1998-04-20 Formes tronquees de proteines apparentees au facteur vegf

Country Status (10)

Country Link
EP (1) EP0977854A2 (fr)
JP (1) JP2001524828A (fr)
KR (1) KR20010020259A (fr)
CN (2) CN1260835A (fr)
AU (1) AU7250298A (fr)
CA (1) CA2287538A1 (fr)
EA (1) EA199900861A1 (fr)
IL (1) IL132537A0 (fr)
NZ (2) NZ514872A (fr)
WO (1) WO1998049300A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
EP0751992B1 (fr) 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Facteur 2 de croissance endotheliale vasculaire
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
DK0848755T4 (da) 1995-09-08 2011-05-23 Genentech Inc VEGF relateret protein
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
AU3072099A (en) * 1998-03-13 1999-09-27 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
AU3203299A (en) * 1998-03-27 1999-10-18 Dorothea J. Eicher Vegf and vegf-c as infant formula supplements
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
DE69928411D1 (de) 1998-09-08 2005-12-22 Agouron Pharma Modifikationen des vegf-rezeptor-2 proteins und verfahren zu seiner verwendung
EP1568375A1 (fr) * 1998-10-26 2005-08-31 Ludwig Institute For Cancer Research Utilisation des protéines VEGF-C ou VEGF-D pour la prévention de la resténose
PT1126870E (pt) * 1998-10-26 2005-01-31 Licentia Ltd Utilizacao do gene vegf-c ou vegf-d ou de uma proteina na prevencao da restenose
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
WO2000024415A2 (fr) 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methodes de regulation de l'angiogenese et de l'integrite vasculaire a l'aide de ligands des recepteurs trk
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US7727971B2 (en) 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
WO2001057181A2 (fr) * 2000-02-04 2001-08-09 Carmeliet, Peter UTILISATION DU FACTEUR DE CROISSANCE ENDOTHELIAL VASCULAIRE, DU FACTEUR DE CROISSANCE DU PLACENTA OU DES DEUX FACTEURS DANS LA PREVENTION OU LE TRAITEMENT DE MALADIES ISCHEMIQUES OU D'ACCIDENTS CEREBROVASCULAIRES
WO2001077328A1 (fr) 2000-04-06 2001-10-18 Franco Wayne P Methodes d'utilisation de facteurs de croissance pour traiter une cardiopathie
EP1157999A1 (fr) * 2000-05-24 2001-11-28 Introgene B.V. Méthodes et moyens pour améliorer la transplantation de la peau en utilisant des vecteurs d'apport de genes munis d'un tropisme pour des fibroblastes primaires ainsi que d'autres utilisations de celles-ci
WO2002011769A1 (fr) 2000-08-04 2002-02-14 Human Genome Sciences, Inc. Facteur 2 de croissance endothéliale (vegf-2)
EP1323736A4 (fr) * 2000-08-10 2005-08-24 Masabumi Shibuya Facteur de croissance chimere de cellules endotheliales vasculaires de type humain
EP1191104A1 (fr) * 2000-09-26 2002-03-27 Introgene B.V. Vehicules de trasport génique et leur utilisation dans preparations medicaux et de vaccines
AU2884102A (en) 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
EP1385864B1 (fr) 2001-04-13 2010-06-09 Human Genome Sciences, Inc. Anticorps anti-VEGF-2
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
JP2005505510A (ja) * 2001-06-20 2005-02-24 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Vegf−bによる血管新生の刺激
JP4418676B2 (ja) 2001-10-15 2010-02-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 虚血性損傷を減らすための置換された4−フェニル−4−(1h−イミダゾール−2−イル)−ピペリジン誘導体
WO2006055743A2 (fr) * 2004-11-18 2006-05-26 Franco, Wayne Combinaison de therapie au facteur de croissance et de therapie cellulaire pour le traitement de maladies aigues et chroniques des organes
WO2010078624A1 (fr) * 2009-01-07 2010-07-15 Vegenics Limited Matériaux et méthodes pour le traitement de l’hypertension

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1242149B (it) * 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
WO1994011506A1 (fr) * 1992-11-18 1994-05-26 Arch Development Corporation Transfert de genes au moyen d'un adenovirus au muscle lisse cardiaque et vasculaire
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6100242A (en) * 1995-02-28 2000-08-08 The Regents Of The University Of California Gene therapies for enhancing cardiac function
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
ES2206558T3 (es) * 1995-03-02 2004-05-16 Amrad Operations Pty.,Ltd. Nuevo factor de crecimiento y secuencia genetica que lo codifica.
EP0873348A4 (fr) * 1995-06-06 2000-11-08 Human Genome Sciences Inc Facteur de croissance 3 de l'endothelium vasculaire humain

Also Published As

Publication number Publication date
IL132537A0 (en) 2001-03-19
CN1260835A (zh) 2000-07-19
WO1998049300A3 (fr) 1999-03-11
NZ500530A (en) 2001-12-21
JP2001524828A (ja) 2001-12-04
EA199900861A1 (ru) 2000-06-26
EP0977854A2 (fr) 2000-02-09
WO1998049300A2 (fr) 1998-11-05
AU7250298A (en) 1998-11-24
KR20010020259A (ko) 2001-03-15
CN1680442A (zh) 2005-10-12
NZ514872A (en) 2005-01-28

Similar Documents

Publication Publication Date Title
CA2287538A1 (fr) Formes tronquees de proteines apparentees au facteur vegf
EP0925360B1 (fr) Facteur angiogeniqueutilisation de facteur angiogenique vegf145 dans le traitement de maladies cardiovasculaires
US6479654B1 (en) Forms of the angiogenic factor vascular endothelial cell growth factor: VEGF
JP2000069982A (ja) ヒト血管内皮増殖因子2
CA2220912A1 (fr) Facteur de croissance humain du type ccn
CA2322748A1 (fr) Facteur de croissance endothelial vasculaire 2
JP2002541829A (ja) 遺伝子治療および治療的スクリーニングに有用なeNOS変異体
US20030165467A1 (en) Angiogenic factor and use thereof in treating cardiovascular disease
EP1141293A2 (fr) Facteur de croissance endotheliale vasculaire- x
EP0796325A1 (fr) Facteur de croissance vasculaire humain proche de la proteine de fixation du facteur de croissance insulinoide
US20020034738A1 (en) Human vascular ibp-like growth factor
US6287812B1 (en) Nucleic acid molecules encoding cytostatin I
EP1426444A2 (fr) Utilisation du facteur d'angiogénèse VEGF145 dans le traitement de maladies cardiovasculaires
US20060084622A1 (en) Angiogenic factor and use thereof in treating cardiovascular disease
Neufeld et al. VEGF 145 expression vectors
AU8936101A (en) Angiogenic factor and use thereof in treating cardiovascular disease
KR100407087B1 (ko) 사람혈관성ibp-유사성장인자
AU2004200697A1 (en) Variants of the Angiogenic Factor Vascular Endothelial Cell Growth Factor: VEGF
CA2206640A1 (fr) Facteur de croissance vasculaire humain proche de la proteine de fixation du facteur de croissance insulinoide
JP2002247983A (ja) ヒト血管ibp様成長因子

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued